Stocktoria
Amphastar Pharmaceuticals, Inc. AMPH
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2014-06-25
Amphastar Pharmaceuticals, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $719.9M | $732.0M | $644.4M | $499.0M | $437.8M |
| Gross profit | $356.1M | $373.9M | $351.1M | $248.9M | $199.7M |
| R&D expense | $85.8M | $73.9M | $73.7M | $74.8M | $60.9M |
| Operating income | $140.4M | $205.4M | $197.0M | $107.5M | $69.9M |
| Interest expense | — | — | $27.2M | $1.8M | $885,000 |
| Income tax | $25.5M | $29.7M | $31.8M | $23.5M | $20.6M |
| Net income | $98.1M | $159.5M | $137.5M | $91.4M | $62.1M |
| EPS (diluted) | $2.03 | $3.06 | $2.60 | $1.74 | $1.25 |
| Operating cash flow | $156.1M | $213.4M | $183.5M | $89.2M | $98.0M |
| Free cash flow | $121.2M | $172.3M | $145.3M | $65.1M | $70.5M |
| Cash & equivalents | $170.2M | $151.6M | $144.3M | $156.1M | $126.4M |
| Inventory | $176.9M | $153.7M | $105.8M | $103.6M | $92.8M |
| Total assets | $1.6B | $1.6B | $1.5B | $742.0M | $671.5M |
| Total liabilities | $840.5M | $845.2M | $873.5M | $213.3M | $226.0M |
| Shareholders' equity | $788.8M | $732.3M | $639.4M | $528.7M | $445.5M |
Source: SEC EDGAR filings · CIK 0001297184 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.